Theory Paper IIDrNB Cardiology – Theory Notes

CARDIAC AMYLOIDOSIS; CURRENT STATUS OF DIAGNOSIS

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ITHE DIAGNOSTIC PARADIGM SHIFT (GILLMORE ALGORITHM / ESC 2021-2023 / ACC 2023)

  • Two Dominant Clinical Subtypes (>95% of All Cardiac Amyloidosis):
    • Immunoglobulin Light-Chain (AL) Amyloidosis: Clonal plasma cell dyscrasia secreting misfolded lambda (75–80%) or kappa (20–25%) immunoglobulin light chains; medical emergency with <6-month untreated survival if severe cardiac involvement is present.
    • Transthyretin (ATTR) Amyloidosis: Misfolding of hepatic transthyretin (prealbumin) tetramers into amyloid fibrils, divided into Wild-Type ATTR (ATTRwt, formerly “senile systemic amyloidosis”) (predominantly older men >=65 yr) and Hereditary/Variant ATTR (ATTRv) (autosomal dominant TTR gene mutations such as Val122Ile [p.Val142Ile], Thr60Ala, and Val30Met).
    • The Non-Invasive Diagnostic Revolution: Based on the landmark validation by Gillmore et al. (Circulation 2016), ATTR Cardiac Amyloidosis can be diagnosed with ~100 percent specificity and positive predictive value WITHOUT an invasive biopsy when Grade 2 or 3 myocardial uptake on bone-avid radiotracer scintigraphy is combined with complete absence of a monoclonal protein in serum and urine.

IIEXTRACARDIAC AND CARDIOVASCULAR “RED FLAGS” (WHEN TO SUSPECT AMYLOIDOSIS)

  • Orthopedic and Soft-Tissue Red Flags (Frequently Precede Heart Failure by 5 to 10 Years in ATTR):
    • Bilateral Carpal Tunnel Syndrome (most common early sign, present in ~50% of ATTRwt 5 to 10 years before cardiac diagnosis).
    • Lumbar Spinal Canal Stenosis (ligamentum flavum amyloid infiltration).
    • Spontaneous Distal Biceps Tendon Rupture (“Popeye Sign”) (present in ~33% of ATTRwt) and trigger finger / total hip or knee arthroplasty.
    • Pathognomonic Mucocutaneous Signs of AL Amyloidosis: Macroglossia (tongue enlargement with lateral dental indentations) and periorbital purpura (“raccoon eyes”) after minor coughing/Valsalva, alongside nephrotic-range proteinuria and hepatomegaly.
    • Neurological Red Flags: Sensorimotor peripheral polyneuropathy (ascending numbness/pain, classic in ATTRv and AL) and dysautonomia (profound orthostatic hypotension, postprandial diarrhea/constipation, erectile dysfunction, and urinary retention).
    • Cardiovascular Phenotypic Clues:
    • Voltage-to-Mass Discordance: Marked concentric biventricular wall thickening (>=12 to 14 mm) on echocardiography paired with low QRS voltage (all limb leads <=5 mm or precordial leads <=10 mm; present in ~50–60% of AL and ~25–30% of ATTR) or absence of expected LVH voltage with a “pseudo-infarction” QS pattern in anterior/inferior leads (present in 50 to 70% despite clean coronary arteries).
    • “Auto-Cure” of Hypertension and GDMT Intolerance: A previously hypertensive patient whose blood pressure spontaneously normalizes or who develops severe hypotension/bradycardia on low doses of ACEi/ARB/ARNI or Beta-Blockers.
    • Specific High-Prevalence Cohorts: 13 to 16 percent of elderly patients undergoing TAVR for severe Aortic Stenosis (especially Low-Flow, Low-Gradient severe AS), 13 to 17 percent of hospitalized HFpEF patients with LV wall thickness >=12 mm, and middle-aged/older adults with unexplained Complete Heart Block or Atrial Fibrillation.

IIISTEP 1: MANDATORY LABORATORY EXCLUSION OF AL AMYLOIDOSIS (ALL THREE TESTS REQUIRED)

  • The Cardinal Rule: Because up to 20 to 30 percent of patients with AL Cardiac Amyloidosis can also show false-positive Grade 1, 2, or 3 myocardial uptake on Tc-99m PYP/DPD bone scintigraphy, a bone scan can NEVER be interpreted in isolation without simultaneously ordering the Monoclonal Protein Triad:
  • Serum Free Light Chain (sFLC) Assay (Quantitative Kappa and Lambda Free Light Chains + Kappa/Lambda Ratio): Normal serum kappa/lambda ratio is 0.26 to 1.65 (extended to 0.37 to 3.10 in severe CKD / eGFR <30 mL/min because free light chains are renally cleared).
  • Serum Protein Electrophoresis with Immunofixation (SPIE / SIFE).
  • 24-Hour (or Spot) Urine Protein Electrophoresis with Immunofixation (UPIE / UIFE).
  • Crucial Exam Trap: Standard Serum Protein Electrophoresis (SPEP) alone is insufficient (sensitivity only ~50 to 70% in AL because the monoclonal light-chain spike is often too small to form an M-band on standard SPEP); combining sFLC + SIFE + UIFE achieves >99 percent sensitivity for detecting AL Amyloidosis.

IVSTEP 2: MULTIMODALITY ECHOCARDIOGRAPHY AND CARDIAC MRI

  • Transthoracic Echocardiography and 2D Speckle-Tracking Strain:
    • Structural Hallmarks: Concentric LV and RV free-wall thickening (>=12 mm; RV free wall >5 mm), thickened interatrial septum and AV valve leaflets, bi-atrial dilation, small pericardial effusion, and Grade III restrictive mitral inflow (E/A >2.0, deceleration time <150 ms, e’ <5 cm/s, E/e’ >15).
    • The “Cherry-on-Top” Apical Sparing Bull’s-Eye Pattern: Profound impairment of longitudinal strain in the basal and mid-ventricular segments with preserved strain at the LV apex (Relative Apical Longitudinal Strain ratio = [Average Apical LS] / [Average Basal LS + Average Mid LS] >= 1.0).
    • Cardiac Magnetic Resonance (CMR — Reference Tissue Characterization):
    • Late Gadolinium Enhancement (LGE) and Nulling Kinetics: Diffuse circumferential subendocardial or transmural LGE (often involving the right ventricle and both atria) accompanied by abnormal gadolinium inversion-time (TI) kinetics—on the TI scout sequence, the amyloid-infiltrated myocardium reaches the null point (turns black) BEFORE or simultaneously with the LV blood pool.
    • Parametric Mapping: Markedly elevated Native T1 (>1,100 to 1,150 ms at 1.5T) and massively expanded Extracellular Volume (ECV >= 40 percent, often 50 to 70 percent)—the highest ECV values seen in any cardiomyopathy.
Diagnostic Step / Modality Specific Finding / Cut-off Clinical Action / Interpretation
Step 1: Monoclonal Screen sFLC (Kappa/Lambda ratio) + SIFE + UIFE If ANY test is abnormal -> Non-invasive pathway STOPS; urgent Hematology + Tissue Biopsy with Mass Spectrometry
Step 2: Echo & CMR Wall thickness >=12 mm + Apical Sparing GLS (“Cherry-on-Top”); CMR subendocardial/transmural LGE, abnormal TI nulling, & ECV >=40% Confirms cardiac amyloid phenotype; does not reliably differentiate AL from ATTR (requires Step 1 + Step 3)
Step 3: Tc-99m PYP / DPD / HMDP Bone Scintigraphy + SPECT Perugini Grade 2 or 3 (Heart/Contralateral Lung [H/CL] ratio >=1.5 at 1h or >=1.3 at 3h) + Negative sFLC/SIFE/UIFE 100% Specificity & PPV for ATTR Cardiac Amyloidosis (No biopsy required)
Step 4: TTR Gene Sequencing Sanger / NGS sequencing of the TTR gene Class I Mandatory in all confirmed ATTR-CM to distinguish ATTRwt from ATTRv (cascade family screening)

VSTEP 3: BONE-AVID RADIOTRACER SCINTIGRAPHY (THE NON-INVASIVE ATTR CONFIRMATION)

  • Radiotracers: Technetium-99m Pyrophosphate (Tc-99m PYP), Tc-99m 3,3-diphosphono-1,2-propanodicarboxylic acid (Tc-99m DPD), or Tc-99m Hydroxymethylene Diphosphonate (Tc-99m HMDP). (Crucial Exam Trap: Tc-99m MDP [Methylene Diphosphonate], the standard orthopedic bone scan tracer used in many general radiology departments, has low sensitivity for cardiac ATTR and must NOT be used.)
  • Perugini Visual Grading Scale (at 1 or 3 Hours Post-Injection) + Mandatory Tomographic SPECT:
    • Grade 0: No myocardial uptake and normal bone/rib uptake.
    • Grade 1: Myocardial uptake less than rib uptake.
    • Grade 2: Myocardial uptake equal to rib uptake.
    • Grade 3: Myocardial uptake greater than rib uptake with mild or absent rib uptake.
    • Mandatory SPECT Confirmation: Planar Heart-to-Contralateral Lung (H/CL >= 1.5 at 1 hour or >= 1.3 at 3 hours) ratios alone can be falsely positive due to residual radiotracer in the LV blood pool (especially in low-output heart failure or CKD); therefore, 3D SPECT/CT imaging is mandatory to verify that radiotracer uptake is truly within the left ventricular myocardium rather than the cavity blood pool.
    • The Non-Invasive Diagnostic Rule (Class I): Perugini Grade 2 or 3 myocardial uptake on SPECT + Negative sFLC, Negative SIFE, and Negative UIFE confirms ATTR Cardiac Amyloidosis with 100% specificity without endomyocardial biopsy.

VISTEP 4: WHEN INVASIVE BIOPSY AND MASS SPECTROMETRY ARE REQUIRED, PLUS TTR GENOTYPING

  • Strict Indications for Histological Biopsy (Endomyocardial Biopsy or Surrogate Fat Pad / Bone Marrow Biopsy):
    • Scenario A — Positive Monoclonal Protein Screen (Abnormal sFLC, SIFE, or UIFE): Regardless of whether the PYP scan is Grade 0 or Grade 2/3 (since MGUS coexists in 20 to 40 percent of elderly ATTRwt patients, and AL can show Grade 2/3 PYP uptake), histological biopsy with fibril typing is mandatory before starting chemotherapy or TTR stabilizers. (Note: Abdominal fat pad aspirate has ~80–85% sensitivity in systemic AL, ~45–65% in ATTRv, and only ~15% in ATTRwt; therefore, Endomyocardial Biopsy [EMB] is often required when fat pad biopsy is negative.)
    • Scenario B — Negative Monoclonal Screen with Equivocal Grade 1 PYP Scan (or Grade 0 PYP scan when high suspicion of rare TTR variants like Phe64Leu/Ser77Tyr or ApoA-I amyloidosis exists).
    • Histopathology and Gold-Standard Fibril Typing:
    • Congo Red Staining: Demonstrates salmon-pink deposits under light microscopy and pathognomonic apple-green birefringence under cross-polarized light (or Thioflavin T/S fluorescence).
    • Laser Microdissection and Liquid Chromatography–Tandem Mass Spectrometry (LMD-LC-MS/MS): The gold standard (near-100 percent specificity) for definitive amyloid precursor protein typing on biopsy tissue (superior to immunohistochemistry, which can yield false results due to serum protein contamination).
    • Mandatory TTR Gene Sequencing (Class I in All Confirmed ATTR-CM): Every patient diagnosed with ATTR Cardiac Amyloidosis—regardless of age—must undergo TTR genetic sequencing to differentiate wild-type (ATTRwt) from hereditary/variant (ATTRv) disease, triggering cascade genetic testing of first-degree relatives and unlocking access to TTR gene silencers.

Key references

  • Gillmore JD, Maurer MS, Falk RH, et al.: Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis, Circulation, 2016.
  • Garcia-Pavia P, Rapezzi C, Adler Y, et al.: Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases, European Heart Journal, 2021.
  • Kittleson MM, Ruberg FL, Ambardekar AV, et al.: 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis, Journal of the American College of Cardiology, 2023.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.